Amgen reported strong Q2 results with product sales growing 8%, driven by key products like Neulasta and Enbrel. The company raised its full-year revenue and EPS guidance to the upper end of the range, reflecting management's confidence in continued growth. This positive outlook and improved guidance are likely to boost investor sentiment and positively impact the stock price in the short term.

[1]